1150618-07-7 Usage
Preparation
Methyl-3-bromo-4-methyl-5-nitropicolinate synthesis: 3-bromo-2-iodo-4-methyl-5-nitropyridine (129.0 g, 0.38 mol) and (Ph3P)2PdCl2 (7.92 g, 3 mol%) were suspended in CH3CN (1300 mL) and MeOH (430 mL) and Et3N (79.3 mL, 1.5 eq) was added. The mixture was transferred to a steel 5000 mL pressure vessel, 4 bar of CO pressure was applied and the reaction mixture was slowly heated to 80 oC. Subsequently, it was stirred for 5 h at this temperature, then allowed to cool overnight. The volatiles were removed in vacuo, the residue was stirred in EtOAc (1000 mL) and filtered. The residue was extracted with EtOAc (2*250 mL) and the combined filtrates were washed with brine (1000 mL) and dried on Na2SO4. The volatiles were removed in vacuo, affording 120 g of a brown oil. This was coated on 120 g of silicagel and purified by column chromatography (3500 g of silica gel, EtOAc/heptane 1:3, KMnO4 staining). The appropriate fractions were combined and concentrated to give Methyl-3-bromo-4-methyl-5-nitropicolinate as a beige solid (63.5 g, 61%).
Check Digit Verification of cas no
The CAS Registry Mumber 1150618-07-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,0,6,1 and 8 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1150618-07:
(9*1)+(8*1)+(7*5)+(6*0)+(5*6)+(4*1)+(3*8)+(2*0)+(1*7)=117
117 % 10 = 7
So 1150618-07-7 is a valid CAS Registry Number.
1150618-07-7Relevant articles and documents
Discovery of an HIV integrase inhibitor with an excellent resistance profile
Pryde, David C.,Webster, Rob,Butler, Scott L.,Murray, Edward J.,Whitby, Kevin,Pickford, Chris,Westby, Mike,Palmer, Michael J.,Bull, David J.,Vuong, Hannah,Blakemore, David C.,Stead, Darren,Ashcroft, Christopher,Gardner, Iain,Bru, Claire,Cheung, Wai-Yee,Roberts, Ieuan O.,Morton, Jennifer,Bissell, Richard A.
, p. 709 - 719 (2013/06/05)
In the present article, we describe SAR studies within a series of N-hydroxy-dihydronaphthyridinone HIV integrase inhibitors that led to a candidate compound, PF-4776548, of high potency and with an excellent resistance profile. Uncertainties around the h
